#platinum-resistant ovarian cancer

19 Oct 2026

Cyclin E1 predicts survival with azenosertib

In a Phase II study, Cyclin E1‑positive patients lived a median 15.8 months, compared with 7.5 months for Cyclin E1‑negative.

Read more